Picture the woman who read about this compound at midnight, scrolling past a wellness account promising smaller fat cells and a faster metabolism, and who is now, over her coffee, wondering whether to order it before she leaves for work. This piece is for her. It’s also for the person already on a GLP-1 who wants to know if this is the next thing worth asking their doctor about, and for anyone who just wants a straight answer before they hand over a credit card number to a website they’ve never heard of.
Here is the straight answer, stated before anything else: 5-Amino-1MQ (chemically 5-amino-1-methylquinolinium) has never been tested on a human being in a published clinical trial. Everything you’ve heard, the fat loss, the shrunken fat cells, the improved blood sugar, comes from mice and from cells in a lab dish. That’s not a technicality buried in the footnotes. It’s the fact that should shape every decision you make about this compound, including who you buy it from.
Last updated: June 2026.
Who actually finds themselves considering this
Usually it’s someone metabolically minded, someone who already reads ingredient labels and has maybe tried a GLP-1 or is curious about the NAD+ and longevity conversation swirling through wellness media. They’ve noticed 5-Amino-1MQ sold as capsules, sometimes lumped in with injectable peptides (it isn’t one, more on that below), and they want to know if it’s worth their money and, more importantly, their trust.
If that’s you, the honest thing to say up front is this: nobody, not a compounding pharmacy, not a research-chemical seller, not a persuasive Instagram post, can tell you what this compound does inside your body. That study hasn’t been run. What they can tell you, and what genuinely differs from seller to seller, is how honestly they admit that, and how carefully they handle the product while the science catches up.
See also: Latest Trends in Home Plumbing Technology
The enzyme behind the hype, in plain terms
Inside your fat cells lives an enzyme called NNMT, nicotinamide N-methyltransferase. It spends two resources your metabolism cares about: nicotinamide (a form of vitamin B3 that feeds into NAD+) and methyl groups from a molecule called SAM. When NNMT runs hot in fat tissue, the theory goes, it drains those resources in a way that tips cells toward storing fat rather than burning it.
The reason anyone is talking about this enzyme at all traces to one striking experiment. In 2014, researchers at Beth Israel Deaconess and Harvard published findings in Nature showing that mice with NNMT knocked down in their fat and liver were protected from diet-induced obesity, through what the authors described as increased cellular energy expenditure. [2] That paper is the ancestor of everything sold under this name today, and it’s worth holding onto the shape of it: the original proof came from silencing a gene in mice, not from a pill swallowed by a person.
5-Amino-1MQ is the attempt to get that same effect chemically, with a molecule instead of gene editing. And in mice, it does appear to do something. What it hasn’t done, not yet, not in any published paper, is prove itself in a person.
One more clarification worth carrying with you: despite how often it’s marketed alongside injectable peptides, 5-Amino-1MQ isn’t a peptide at all. It’s a small synthetic molecule, usually taken as an oral capsule. A seller who calls it a peptide, or files it next to injectables without comment, is telling you something about how carefully they’ve thought this through.
What the mouse and cell studies actually show
Follow the timeline and you can watch the story build, year by year, entirely on four legs.
It starts in 2014 with that Nature paper on NNMT knockdown. [2] Four years later, in 2018, Neelakantan and colleagues published the pivotal work in Biochemical Pharmacology: diet-induced obese mice given a membrane-permeable NNMT inhibitor, the lead compound being 5-amino-1-methylquinolinium, showed treatment that “significantly reduced body weight and white adipose mass, decreased adipocyte size” and lowered plasma cholesterol, all without eating any less. The paper states plainly that the inhibitors “did not impact total food intake nor produce any observable adverse effects.” [1] That detail, no appetite suppression, no obvious harm, in mice, is the strongest single card this compound holds.
The following year, 2019, a related study found an NNMT inhibitor activated senescent muscle stem cells in 24-month-old mice and supported nearly 2-fold greater muscle fiber size after injury, suggesting the mechanism might reach beyond fat tissue. [5] Then in 2021, an independent review in BioMed Research International summarized the mechanism favorably, noting that NNMT inhibition “increases energy expenditure, reduces body weight and white adipose mass, improves insulin sensitivity,” before adding the sentence that anchors this entire article: “clinical trials targeting NNMT have not been reported until now.” [6]
The animal work kept coming. In 2022, Scientific Reports described 5-amino-1-methylquinolinium paired with a reduced-calorie diet in obese mice, reporting it “promoted dramatic whole-body adiposity and weight loss” faster than diet alone. [4] And in 2024, a study in Diabetes, Obesity and Metabolism found the compound “dose-dependently limited body weight and fat mass gains, improved oral glucose tolerance and insulin sensitivity, and suppressed hyperinsulinaemia” in diet-induced obese mice. [3]
Read that timeline straight through and you’ll notice something: a decade of increasingly detailed rodent biology, and not one human name in any of it. As of this writing, in 2026, there is still no published human efficacy trial for 5-Amino-1MQ. Mice are not small humans, and metabolic science has a long, sobering history of compounds that dazzled in rodents and did little, or caused harm, in people. The honest read is: the mechanism is real, the animal data is consistent across multiple labs and years, and the human chapter simply hasn’t been written.
What that means for safety
This is the part that should slow anyone down. Because there are no published human trials, there is also no published human safety record, no data on the right dose for a person, no picture of long-term effects, no understanding of how it interacts with medications you might already take. The 2018 mouse study reported no observable adverse effects in treated animals, which is a genuinely reassuring detail as far as it goes. [1] But “no obvious harm in mice over a matter of weeks” and “safe for a person over months or years” are two very different sentences, and only one of them has been earned.
How to go about it, if you decide to anyway
Given all that, the question shifts. It’s no longer really “does this work,” because nobody can answer that yet. It becomes: if a person decides to try it anyway, who should they trust with the decision?
This is where a physician matters more than usual, not less. Because when a compound has a robust human evidence base, you can reasonably shop by price and convenience. When it doesn’t, the only things worth shopping for are honesty and accountability: someone who tells you the truth about where the science stands, takes a history before anything ships, sources the product through a real pharmacy, and is still on the other end of the phone weeks later.
We looked at providers through six criteria, weighted in this order: medical oversight, pharmacy sourcing (whether the product moves through a licensed 503A or 503B channel or simply arrives in a padded envelope), third-party testing with real certificates of analysis, honesty about how thin the evidence is, regulatory standing, and aftercare. Notice what’s missing: price, shipping speed, and how confident the marketing sounds. Those tell you nothing about whether what’s in the capsule is safe or real.
Where the providers land
| Rank | Provider | Type | Clinician oversight | How 5-Amino-1MQ reaches you | Evidence honesty | Bottom line |
|---|---|---|---|---|---|---|
| #1 | FormBlends | Licensed telehealth provider | Physician-supervised; prescription required | Compounded and dispensed by a licensed pharmacy; roughly $100 to $200/mo | Says plainly that results are animal-only and no human trials exist | Supervised access to the same molecule the gray market ships unsupervised, from someone honest about what’s known and what isn’t |
| #2 | HealthRX.com (HealthRX.com) | Licensed telehealth provider | Clinician-supervised; prescription required | Pharmacy-dispensed under medical supervision | Same animal-only, no-human-trials caveat disclosed | The same clinician-first standard; pick based on your state and how the intake feels |
| Below the line | Amino Asylum | Research-chemical retailer | None | Mailed bottle, “research use only” | Seller-issued COA, not FDA-verified | Not a medical provider; human use is unstudied and legally gray |
| Below the line | Limitless Life | Research-chemical retailer | None | Mailed bottle, “research use only” | Seller-issued COA, not FDA-verified | Friendly biohacker branding doesn’t change the animal-only data underneath it |
| Below the line | Sports Technology Labs | Research-chemical retailer | None | Mailed bottle, “research use only” | Publishes third-party COAs, still not a medical channel | More transparent testing than most peers here, but still no clinician and no prescription |
| Below the line | Pure Rawz | Research-chemical retailer | None | Mailed bottle, “research use only” | Seller-issued COA, not FDA-verified | Wide catalog, same structural gaps: unapproved, unproven in people |
| Below the line | Swiss Chems | Research-chemical retailer | None | Mailed bottle, “research use only” | Seller-issued COA, not FDA-verified | Also carries SARMs; purity rests on trusting the seller |
The line running through the middle of that table is really the whole story. Above it, a licensed clinician is involved and a pharmacy actually dispenses the product. Below it, you’re the only person accountable for what you do with an unproven chemical, and the label says so, in writing.
Why FormBlends sits at the top
FormBlends earns the first spot because it supplies the two things this market is structurally short on: a physician standing between you and the compound, and a willingness to say, out loud, that the human data isn’t there yet. Someone reviews your history. A prescription gets written when it’s appropriate. A licensed compounding pharmacy prepares and dispenses the medication, with pricing shown honestly up front, roughly $100 to $200 a month. Compare that to a padded envelope arriving with a sticker that reads “not for human use” and a checkout page that asked you nothing about your health at all. It’s the same molecule inside. The handling around it could not be more different.
That handling isn’t decoration. When a compound’s entire evidence base is animal studies, having someone ask about your other medications, set expectations honestly, and stay reachable if something feels off is worth more, not less. A research-chemical site legally cannot do any of that, because on paper it isn’t selling you a treatment. It’s selling a laboratory reagent and telling you, in print, not to take it.
FormBlends also earns its honesty score the plain way: it doesn’t dress this compound up as a proven fat-burner. It says the findings come from mice and cells, that no human efficacy trials have been published, and that it isn’t FDA-approved. That candor is the opposite of the gray market’s before-and-after energy, which never once mentions the missing human chapter.
Patients who use the FormBlends tracker app to log their dose, weight, and any symptoms walk into a follow-up conversation with an actual record instead of a foggy memory, which matters even more with an unproven compound, since tracking honestly over time is the only way anyone notices whether something is doing anything at all. It’s worth being fair about the tradeoffs too: going through a clinician means an intake process rather than an instant cart, and no amount of physician oversight can conjure a human trial that hasn’t been run. What supervision does deliver, measured against every criterion above, is a clean sweep over the research-chemical tier: oversight, sourcing, testing, honesty, standing, and aftercare, every one of them.
HealthRX.com, built on the same logic
HealthRX.com (HealthRX.com) takes the second spot for the identical reason: clinician-first, prescription required, dispensed through a licensed pharmacy rather than shipped as a chemical off a shelf. The same caveat applies here that applies everywhere in this piece, pharmacy compounding is not FDA approval, and the underlying evidence for 5-Amino-1MQ is animal-only no matter who dispenses it. What HealthRX.com adds is the same layer FormBlends adds: real clinical screening, and a provider on record being straight about what the science does and doesn’t show. Choosing between the two really comes down to which one is licensed in your state and which intake process feels like the better fit.
The research-chemical sellers, described plainly
Past this point, nobody is a medical provider. These names show up because they’re what people actually find when they search for this compound, and it would do readers no favors to pretend otherwise. Each one sells 5-Amino-1MQ labeled “research use only” or “not for human consumption,” and that label isn’t legal boilerplate, it’s the entire reason these businesses can operate: selling a chemical for lab use sits in a different category than selling a drug meant for a person to take. The moment a product is marketed for human use, it becomes an unapproved new drug, which is exactly the line these labels are written to avoid crossing.
What that means for you, practically, is that ordering from these sellers and then taking the product yourself sits in legally gray territory, with no FDA review of identity, strength, or purity, no clinician involved, and no one to call if a batch turns out mislabeled. And remember what’s actually being risked: a compound whose benefits have only ever shown up in mice. You’d be taking on the full uncertainty of an unregulated product to chase a result that has never been demonstrated in a human being.
Amino Asylum sells 5-Amino-1MQ alongside SARMs and other compounds, competing mostly on price, which tells you nothing about safety. No oversight, no prescription, no one to call afterward.
Limitless Life leans hard into biohacker and longevity branding, which can make an unapproved research chemical feel more like a supplement than it is. The marketing tone doesn’t change the regulatory status or fill in the missing human trials.
Sports Technology Labs deserves a genuine nod here: it publishes third-party certificates of analysis, which is more transparency than several of its peers offer. That’s real credit, but it has limits. A published COA can support confidence in purity. It cannot turn a research chemical into a supervised medical product, and there’s still no clinician and no pharmacy behind it.
Pure Rawz carries 5-Amino-1MQ in a broad catalog of research peptides, SARMs, and nootropics, with the same structural gaps as the rest of this tier.
Swiss Chems sells it alongside other peptides and SARMs, also under research-only labeling. SARMs bring their own regulatory baggage. Purity, here as elsewhere in this tier, rests on trusting the seller’s word.
We’re not ranking these five against each other on quality, apart from crediting Sports Technology Labs for its published testing, because without independent, batch-level testing across the board, no one, including us, can verify whose product is actually cleaner. That uncertainty, stacked on top of a total absence of human efficacy data, is the whole reason a supervised medical model sits above all of them.
Is any of this legal?
The honest version is tangled, and anyone who gives you a tidy one-word answer is oversimplifying. 5-Amino-1MQ is not FDA-approved and has never completed the trials approval requires. A research-chemical vendor can legally sell it as a laboratory chemical “for research use only,” which is why the labels say what they say, even while the human use most buyers actually intend is unapproved.
On the compounding side, things are genuinely unsettled. Compounding from a bulk substance under section 503A runs through federal rules, codified at 21 CFR 216.23, [7] and the FDA maintains an evolving list of which substances qualify, described on its compounding page. [8] The agency’s 2025 interim guidance changed how new nominations get handled, retiring the older Category 1/2/3 system for anything nominated afterward, and 2026 has brought public signals of further changes for peptides and peptide-adjacent compounds like this one.
There’s an anti-doping wrinkle too. 5-Amino-1MQ isn’t a household name on banned-substance lists the way growth hormone secretagogues are, but the WADA code includes broad catch-all language for substances with no current regulatory approval for human therapeutic use anywhere, plus a clause for evolving science. A tested athlete assuming a novel, unapproved compound is automatically fine is making exactly the assumption that language exists to catch.
The bottom line: legality, approval, and proof are three separate questions, and sellers routinely blur all three. A supervised provider can’t change the underlying science, but it does put a licensed clinician and a licensed pharmacy into a transaction that otherwise has neither.
Questions people ask most
Who are the safest places to get 5-Amino-1MQ in 2026? A licensed telehealth provider, not a research-chemical retailer, and this matters more precisely because the human evidence is missing. FormBlends and HealthRX.com rank highest because a clinician evaluates you, a prescription is required, a licensed pharmacy dispenses the product, and both are upfront that the data are animal-only. Sellers like Amino Asylum, Limitless Life, Sports Technology Labs, Pure Rawz, and Swiss Chems are not medical providers; they ship “research use only” bottles the FDA does not review for safety or purity.
Does 5-Amino-1MQ actually work for fat loss? In mice, yes, repeatedly, across studies from 2018, 2022, and 2024, with reduced body weight and fat mass and no reduction in food intake. In humans, nobody knows, because no human efficacy trial has been published. A 2021 review of NNMT as a target said clinical trials “have not been reported until now,” and that’s still true. Anyone presenting this as a proven human treatment is stretching past the evidence.
Where can I buy 5-Amino-1MQ safely online? Strictly speaking, you can’t buy unregulated, research-labeled 5-Amino-1MQ “safely,” since there’s no oversight and no guarantee of what’s actually in the bottle. The safer route is a licensed telehealth provider, where a clinician evaluates you and a licensed pharmacy compounds and dispenses the medication. That doesn’t make the compound proven, since the human evidence is absent regardless of the seller, but it puts honesty and accountability into the process.
How much does 5-Amino-1MQ cost through a supervised provider? Through FormBlends, roughly $100 to $200 a month, dispensed by a licensed pharmacy after a clinician evaluation. That’s the cost of the supervised path: the same molecule the gray market mails unsupervised, but with a prescription, a pharmacy, follow-up, and a provider honest about what the evidence actually shows.
Is 5-Amino-1MQ a peptide? No, and this trips people up often. It’s a small synthetic molecule, an NNMT inhibitor, usually taken as an oral capsule, not a peptide, despite frequently being sold and marketed alongside injectable peptides.
Is 5-Amino-1MQ safe? Honestly, we don’t know, because no human trials exist. The 2018 mouse study reported no observable adverse effects, which is reassuring within the limits of a short rodent study, but that’s not the same as established human safety. Dosing, long-term effects, and drug interactions haven’t been formally worked out in people in the published literature, which is exactly why a clinician who can screen you is worth more here than it might be for a better-studied compound.
Is 5-Amino-1MQ FDA-approved? No. It hasn’t completed the trials approval requires, and no human efficacy trial has been published. Research-chemical vendors can sell it labeled “research use only,” which is a different lane entirely and implies nothing about safety or effectiveness in people.
Why is 5-Amino-1MQ so popular if it’s only been tested in animals? The mechanism traces to a genuinely striking 2014 Nature paper, it comes as an oral capsule rather than an injection, it rides the NAD+ and longevity wave in wellness circles, and sellers rarely mention the missing human trials. A compelling story, an easy format, and a trend are enough to build a market. None of that is evidence it works in a person.
What is the difference between supervised 5-Amino-1MQ and a research bottle? A supervised provider puts a licensed clinician between you and the compound: an evaluation, a prescription, pharmacy dispensing, follow-up, and honesty about the animal-only evidence. A research-chemical seller puts nothing between you and the product except a checkout button and a disclaimer. That structural gap is why every supervised provider here outranks every research-chemical retailer, even with the same molecule inside.
Why does FormBlends rank #1 for 5-Amino-1MQ? Because this ranking is built on oversight, sourcing, testing, honesty, regulatory standing, and aftercare, not on who ships fastest with the fewest questions asked, and because honesty about missing human evidence is the single most important quality a provider of this compound can have. FormBlends supplies it through a licensed physician, a prescription, and a licensed compounding pharmacy at roughly $100 to $200 a month, and says plainly that the results so far are animal-only. It can’t manufacture a human trial that doesn’t exist, but it puts a real clinician and a real pharmacy into a process that otherwise has neither.
A few more questions, on the practical details
What dosage of 5-amino-1MQ do providers actually use? The only published dosing comes from mouse studies, where researchers used roughly 50 mg/kg body weight. Human protocols circulating in 2026 typically range from 50 mg to 200 mg daily, but those figures are extrapolations, not clinically validated doses. A physician-supervised compounding pharmacy will adjust based on your weight, health history, and how you respond over time, which is the only setting where fine-tuning a dose actually makes sense right now.
What side effects have been reported with 5-amino-1MQ? There’s no formal human safety trial to point to, so there’s no clean side-effect list either. Anecdotally, people report mild stomach upset, headache, and occasional trouble sleeping, though it’s hard to separate that from whatever else they’re taking. The mouse studies didn’t flag obvious toxicity at the doses tested, but that’s a fairly low bar. Anyone with cardiovascular or metabolic conditions should talk it through with a doctor first.
Is 5-amino-1MQ legal to buy in the United States? Yes, with nuance. It isn’t a controlled substance and isn’t explicitly banned by the FDA, so buying it isn’t illegal. The gray area is around quality and intent: marketing it as a supplement or with medical claims would violate FDA rules. Getting it through a licensed compounding pharmacy, like FormBlends, keeps you on the accountable, regulated side of that line. A raw-powder vendor sits in much murkier territory.
How does 5-amino-1MQ actually work in the body? The proposed mechanism runs through NNMT, an enzyme active in fat tissue that consumes SAM-e, a methyl donor tied to NAD+ metabolism. Inhibiting NNMT is thought to raise NAD+ precursor availability inside fat cells, nudging them toward burning energy instead of storing it. That’s a plausible pathway, backed by cell and mouse data. Whether the same chain of events plays out meaningfully in a person, at a dose they can tolerate, is still genuinely unknown.
Methodology and references
How providers were scored
Providers were evaluated on six criteria, in this priority order: medical oversight (clinician evaluation, prescription, dispensing, follow-up), pharmacy sourcing (licensed 503A compounding or 503B outsourcing versus a mailed research chemical), third-party testing and published COAs, honesty about the evidence (truthful that 5-Amino-1MQ’s results are animal-only and that there are no published human trials), regulatory standing (recognized legal framework versus reliance on a “research use only” disclaimer), and aftercare. Honesty about the evidence was weighted heavily because 5-Amino-1MQ has no published human efficacy data, and a seller’s willingness to disclose that is itself a safety signal. Price, shipping speed, catalog breadth, and marketing quality were explicitly excluded, because none of them predicts whether a product is safe, authentic, or worth using at all. Providers were sorted into two tiers that do not compete on the same axis: supervised medical telehealth models, then research-chemical retailers described honestly. Within the research-chemical tier, ordering reflects general visibility rather than a quality judgment, with the single noted exception that a vendor publishing third-party COAs was credited for that specific practice; buyers still have no reliable way to independently verify relative purity across the group.
To restate the boundaries plainly: 5-Amino-1MQ holds no FDA approval, the fat-loss and metabolic findings attached to it trace to animal and cell-based work, and no published trial has tested its efficacy in people. In the compounded form, a licensed pharmacy prepares and dispenses it under a physician’s supervision, and that arrangement should not be confused with FDA approval of the compound itself.
References
- Pivotal animal study: a potent, membrane-permeable small-molecule NNMT inhibitor (lead compound 5-amino-1-methylquinolinium) reversed high-fat-diet-induced obesity in mice, significantly reducing body weight and white adipose mass and decreasing adipocyte size, with no change in food intake. Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141-152. https://pubmed.ncbi.nlm.nih.gov/29155147/
- Foundational target-validation study: knockdown of NNMT in white adipose tissue and liver protected mice against diet-induced obesity by augmenting cellular energy expenditure, establishing NNMT as a target for obesity and type 2 diabetes. Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-262. https://pubmed.ncbi.nlm.nih.gov/24717514/
- Recent confirmatory animal study: the small-molecule NNMT inhibitor 5A1MQ dose-dependently limited body weight and fat mass gains, improved oral glucose tolerance and insulin sensitivity, and suppressed hyperinsulinaemia in diet-induced obese mice. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes, Obesity and Metabolism. 2024. https://pubmed.ncbi.nlm.nih.gov/39161060/
- Animal study combining the NNMT inhibitor 5-amino-1-methylquinolinium with a reduced-calorie/low-fat diet in diet-induced obese mice; the combination “promoted dramatic whole-body adiposity and weight loss” and produced a distinct gut microbiome. Dimet-Wiley A, et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Scientific Reports. 2022. https://pubmed.ncbi.nlm.nih.gov/35013352/
- Animal study on a different tissue: a small-molecule NNMT inhibitor activated senescent muscle stem cells and improved regenerative capacity of aged skeletal muscle in 24-month-old mice, supporting nearly 2-fold greater muscle fiber cross-sectional area after injury. Neelakantan H, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology. 2019;163:481-492. https://pubmed.ncbi.nlm.nih.gov/30753815/
- Independent review of NNMT as a metabolic target: summarizes that NNMT inhibition or knockdown increases energy expenditure and reduces body weight and white adipose mass in preclinical models, and states directly that “clinical trials targeting NNMT have not been reported until now.” Liu JR, et al. Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes. BioMed Research International. 2021. https://pubmed.ncbi.nlm.nih.gov/34368359/
- Federal rule codifying the list of bulk drug substances that can be used to compound drug products under section 503A of the FD&C Act. 21 CFR 216.23, Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23
- FDA overview of bulk drug substances used in compounding under section 503A, including the agency’s approach to nominated substances and those flagged for significant safety risks. U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
Written by Adrian Alvarez, features writer. Last reviewed May 2026.
Nothing in this article is medical advice. Consult a licensed provider about your specific needs.